REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
Named Executive Officers
Compensation data for top executives (showing up to 3 years of data)
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Daniel P. Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply | 2025 | $983,382 | $0 | $2,699,728 | $4,049,757 | $965,189 | $82,207 | $8,780,263 |
| 2024 | $964,100 | $0 | $2,699,968 | $4,049,729 | $914,931 | $26,450 | $8,655,178 | |
| 2023 | $931,500 | $0 | $2,699,284 | $4,049,638 | $1,053,527 | $26,200 | $8,760,149 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Andrew J. Murphy, Ph.D. Executive Vice President, Co-Chief Scientific Officer | 2025 | $819,672 | $0 | $2,699,728 | $4,049,757 | $815,164 | $92,798 | $8,477,119 |
| 2024 | $803,600 | $0 | $2,699,968 | $4,049,729 | $783,510 | $26,450 | $8,363,257 | |
| 2023 | $776,250 | $0 | $2,699,284 | $4,049,638 | $877,939 | $26,200 | $8,429,311 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Joseph J. LaRosa Executive Vice President, General Counsel and Secretary | 2025 | $916,062 | $1,000,000 | $1,799,334 | $2,699,810 | $911,024 | $132,740 | $7,458,970 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | 2025 | $1,979,922 | $0 | $0 | $0 | $3,682,655 | $1,617,972 | $7,280,549 |
| 2024 | $1,941,100 | $0 | $0 | $0 | $3,493,980 | $1,387,954 | $6,823,034 | |
| 2023 | $1,875,415 | $0 | $0 | $0 | $4,275,946 | $2,032,977 | $8,184,338 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer | 2025 | $725,000 | $0 | $2,199,751 | $3,299,977 | $721,013 | $39,623 | $6,985,364 |
| 2024 | $660,000 | $0 | $1,999,319 | $2,999,683 | $594,000 | $15,250 | $6,268,252 |
| Executive | Year | Salary | Bonus | Stock Awards | Option Awards | Non-Equity Incentive Comp | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| George D. Yancopoulos, M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | 2025 | $1,979,922 | $0 | $0 | $0 | $3,682,655 | $1,286,892 | $6,949,469 |
| 2024 | $1,941,100 | $0 | $0 | $0 | $3,493,980 | $1,361,703 | $6,796,783 | |
| 2023 | $1,875,415 | $0 | $0 | $0 | $4,275,946 | $1,608,469 | $7,759,830 |